Lilly (Eli) & Co. (LLY) Reports Cyramza Met Primary Endpoint in Phase III
Tweet Send to a Friend
Eli Lilly and Company (NYSE: LLY) announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA™) in combination ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE